# Is SciNote worth committing to long-term as a scientific data management system for pharmaceutical research teams, given the regulatory requirements involved?

<p class="elv-tracking-normal elv-text-default elv-font-figtree elv-text-base elv-leading-base elv-font-normal" elv="true">Posting in the<a class="a a--md" elv="true" href="https://www.g2.com/categories/scientific-data-management-system-sdms"> </a><a class="a a--md" elv="true" href="https://www.g2.com/categories/scientific-data-management-system-sdms">Scientific Data Management System (SDMS) category on G2</a> for pharmaceutical research teams at the long-term commitment decision point for <a class="a a--md" elv="true" href="https://www.g2.com/products/scinote/reviews">SciNote</a>, where the question is not whether SciNote works for general lab documentation but whether it delivers the compliance depth, regulatory durability, and vendor reliability that a pharmaceutical environment demands over a multi-year horizon.</p><p class="elv-tracking-normal elv-text-default elv-font-figtree elv-text-base elv-leading-base elv-font-normal" elv="true">The case for long-term commitment rests on three reviewer-documented pillars: the compliance infrastructure (21 CFR Part 11 e-signatures, full audit trails, role-based access), the quality system integration (one pharma/biotech manufacturer uses SciNote for protocol revision, training documentation, deviation management, CAPAs, and change controls in a single platform), and the support relationship (the team is described as responsive, actively listening, and implementing customer feedback into platform updates). </p><p class="elv-tracking-normal elv-text-default elv-font-figtree elv-text-base elv-leading-base elv-font-normal" elv="true">The FDA and USDA themselves using SciNote provides regulatory credibility that is difficult for alternatives to match. The platform is described as still in active development with some features at an early stage. Pharmaceutical teams with highly specific GxP workflows should verify the maturity of individual features.</p><p class="elv-tracking-normal elv-text-default elv-font-figtree elv-text-base elv-leading-base elv-font-normal" elv="true">For pharmaceutical research teams that have been on SciNote for more than a year, how did the platform perform under actual regulatory scrutiny? Was the audit trail sufficient for your auditors, did the e-signature workflow hold up, and were there any compliance gaps you had to address through workarounds or supplementary documentation?</p>

##### Post Metadata
- Posted at: 4 months ago
- Author title: Marketing Executive
- Net upvotes: 1


## Comments
### Comment 1

The long-term question is impossible to answer by predicting any vendor&#39;s future, so flip it into a question you can answer today: what does leaving look like? Pharma retention obligations mean these records must stay intact and readable for many years, whoever you&#39;re with. So ask for a full export in the demo, and look hard at what comes out: are the audit trails and signature records in it, is the structure usable, or is it a data dump that technically contains everything and practically preserves nothing? A vendor with a clean, complete exit path is safe to commit to precisely because you&#39;re not trapped.

##### Comment Metadata
- Posted at: 4 months ago
- Author title: Tech Consultant





## Related discussions
- [How well does Trello scale into a larger team?](https://www.g2.com/discussions/1-how-well-does-trello-scale-into-a-larger-team)
  - Posted at: over 13 years ago
  - Comments: 6
- [Can we please add a new section](https://www.g2.com/discussions/2-can-we-please-add-a-new-section)
  - Posted at: over 13 years ago
  - Comments: 0
- [Quantifiable benefits from implementing your CRM](https://www.g2.com/discussions/quantifiable-benefits-from-implementing-your-crm)
  - Posted at: over 13 years ago
  - Comments: 4


